PATENT CLAIM ANALYSIS

Application Number: 15909576
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-07
Patent Classification: ["514", "282000"]

Abstract:
Methods of treating patients with dyskinesias, by administering a therapeutically effective amount of a dual-action μ-opioid receptor antagonist/-ϰ-opioid receptor agonists or prodrug thereof to a subject in need thereof, sufficient to mitigate the dyskinesia. Alternatively, a combination of both a μ-opioid receptor antagonist or prodrug thereof, and a ϰ-opioid receptor agonist or prodrug thereof can be administered, either together or separately.

Claim (Index 5):
The method of  claim 1 , wherein said dual action mu-opioid receptor antagonist/kappa-opioid receptor agonist is Nalbuphine or an ester of Nalbuphine.

Metadata:
- Claim Count in Document: 26.0
- Percentile: 90.0
- Lexical Diversity: 1.5814
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14113340', '13445716', '13024298', '14390322', '14170791']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7414112682557604
- 35 USC 102 Novelty (BERT): 0.5422749883869676
- Combined Prediction Score: 0.7214976402688811
- Mean Citation Score: 268.39056600000004
- Max Citation Score: 365.56586
- Similarity Product: 281.5740831279945

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test